Data Support Siglec-15 as Possible Signal in NSCLC and Other Solid Tumors
Source: Cancer Network, November 2024
Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.
Expression of Siglec-15 was reported in tumor-associated macrophages (TAMs) and tumor cells in non–small cell lung cancer (NSCLC) samples and other solid tumor types, according to preclinical findings presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC).
A proprietary monoclonal S15 antibody was developed to determine S15 protein expression on tumor tissue, and an immunohistochemistry (IHC) assay was also developed to detect S15 expression across primary human samples and cell lines. S15 expression was tested across a range of tumor types, where tumor positivity was defined as the detection of at least 1% of S15-positive tumor cells at any intensity level, and TAM positivity was defined as the detection of at least 1 S15-positive TAM in a 20-times field in the tumor microenvironment.